SynthesisFrontiers in genetics2025
Coffin-Lowry syndrome: a systematic review of RPS6KA3 confirmed cases and implications for diagnosis and counseling.
Synthesis in Frontiers in genetics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Challenges in Diagnosis and Management of Coffin-Lowry Syndrome-Single-Center Experience.Diagnostics (Basel, Switzerland) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Coffin-Lowry syndrome (CLS) is a rare X-linked disorder caused by pathogenic variants in Methods: We conducted a systematic review of published cases (n = 72) following PRISMA guidelines. Demographic, phenotypic, and genotypic data were extracted, standardized, and summarized using descriptive statistics. Associations between mutation type and key clinical features were assessed with Chi-square or Fisher's exact tests. Diagnostic approaches and global distribution were also analyzed. Results: The cohort comprised 50 males (69.4%) and 22 females (30.6%), median age 12 years (range: 1-45). Developmental delay (87.5%) and intellectual disability (66.7%) were the most frequent features, alongside musculoskeletal deformities (kyphoscoliosis 33.3%, pectus anomalies 19.4%) and neurologic involvement (SIDEs 12.5%, seizures 15.3%, spasticity 5.6%). Frameshift variants showed the strongest associations with SIDEs (35%, Conclusion: This systematic review highlights recurrent neurodevelopmental, neurologic, and skeletal phenotypes in CLS and delineates mutation-specific risks, particularly for SIDEs and seizures. The findings emphasize the value of comprehensive genomic testing, raise awareness of maternal germline mosaicism, and underscore the utility of reproductive technologies such as PGT-A/M for at-risk families. Beyond clinical and research implications, this work provides an accessible reference for affected families seeking clearer prognostic insights. Systematic Review Registration: Identifier CRD420223404871.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.